Form 4: NeuroOne Medical Technologies CEO David Rosa Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on April 30, 2024, to satisfy tax obligations related to equity awards.
Summary
- On April 30, 2024, David A Rosa, CEO and President of NeuroOne Medical Technologies Corp, disposed of 2,239 shares of common stock.
- The transaction was executed at a price of $1.13 per share.
- The disposition was to cover tax obligations.
- Following the transaction, Rosa directly owns 1,162,597 shares of NeuroOne Medical Technologies Corp.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider transactions. It is common for executives to sell shares to cover tax obligations arising from equity compensation.
Stakeholder Impact
- The disposal of shares by the CEO could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Date of transaction: David Rosa disposed of 2,239 shares of common stock. |
| 05/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.